Cross-border life sciences and health care M&A are well served by dealmakers who know how to price, allocate, and arbitrage the concerns driven by the divergence in regulatory requirements across jurisdictions.

In a number of therapeutic areas and technologies, including oncology, advanced therapies, gene-editing platforms, and AI-enabled therapeutics, global regulators are no longer moving in parallel, with regulatory assessments increasingly reaching different conclusions. Moreover, approval timelines for the same product may routinely diverge by 18 to 36 months based on the applicable jurisdiction.

In response, buyers and sellers are engineering regulatory-risk arbitrage strategies for M&A transactions, namely deals structured around where – and when – approvals are realistically achievable. Under these structures, valuations may be synchronized with the likelihood of the regulatory outcomes, with multi-track consideration structures in which deal economics, closing mechanics and post-closing obligations are calibrated to jurisdiction-specific approval pathways. U.S.-first approvals may command a premium, while Europe-first outcomes often price in delay, heightened compliance friction, and compressed market access. In contrast, China-specific exposure is typically isolated, deferred, or structurally ring-fenced.

Thus, deals increasingly include corridor pricing mechanisms that automatically adjust consideration depending on which clearance arrives first, and on the post-approval obligations attached to each, rather than a traditional earn-out structure based on a binary "approval achieved" basis. Relatedly, these M&A transactions may feature phased closings, jurisdiction-specific conditions precedent, and regulatory migration clauses that reallocate development responsibility if rules shift post-signing (e.g., in response to EU AI Act implementation).

Notably, these transactions may treat the target assets differently across various jurisdictions. EU-facing assets may be ring-fenced in standalone entities to manage MDR or AI Act exposure. Alternatively, buyers may acquire U.S. rights outright while opting to license EU rights. Such bespoke structures may allow assets to be transferred in a sequenced manner that best aligns with the regulatory environment.

By structuring cross-border M&A transactions in a manner that accounts for the divergence in regulatory requirements and processes, buyers monetize speed-to-approval arbitrage, capturing earlier revenue in permissive jurisdictions while deferring or reallocating exposure elsewhere. Sellers unlock earlier liquidity by monetizing assets in favorable regulatory geographies, while retaining expansion optionality. Most importantly, valuation gaps that would once have killed deals are bridged through regulatory-triggered price adjustment rather than abstract risk discounting.

As global regulators continue to diverge in timing and evidence standards, dealmakers would be wise to convert regulatory uncertainty into transactional opportunity.